Viridian Therapeutics, Inc.\DE (VRDN) Price to Sales (2014 - 2026)
Powered by 
Analysis
Viridian Therapeutics, Inc.\DE (VRDN) Price to Sales (2014 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Viridian Therapeutics, Inc.\DE | 2.42 Bn | 2.42 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7,324.60 |
| Mar 31, 2026 | 14,213.34 |
| Dec 31, 2025 | 19,993.03 |
| Sep 30, 2025 | 25.15 |
| Jun 30, 2025 | 15,219.78 |
| Mar 31, 2025 | 15,275.35 |
| Dec 31, 2024 | 21,564.66 |
| Sep 30, 2024 | 20,946.25 |
| Jun 30, 2024 | 11,542.70 |
| Mar 31, 2024 | 15,515.45 |
| Dec 31, 2023 | 13,538.53 |
| Sep 30, 2023 | 9,310.74 |
| Jun 30, 2023 | 14,393.68 |
| Mar 31, 2023 | 11,176.81 |
| Dec 31, 2022 | 8,926.38 |
| Sep 30, 2022 | 690.72 |
| Jun 30, 2022 | 1,286.44 |
| Mar 31, 2022 | 2,047.94 |
| Dec 31, 2021 | 1,101.09 |
| Sep 30, 2021 | 884.47 |